A Rockville, Maryland-based pharmaceutical company received a patent from the U.S. Patent and Trademark Office on Feb. 10 for a new once-daily extended-release nerve pain medication and anticonvulsant.

“With eight U.S. patents now in place for Trokendi XR and seven for Oxtellar XR, we believe we have established a very strong intellectual property position for both products,” said Jack A. Khatter, president and CEO of Supernus Pharmaceuticals Inc. “We are committed to expanding and enhancing our patent coverage to provide our products with the protection they deserve.”

Supernus focuses on the development and commercialization of products treating central nervous system diseases.

The company has two products for epilepsy, and is also developing products for the treatment of impulsive aggression in attention-deficit hyperactivity disorder patients and for the treatment of ADHD.

Supernus’ stock price closed at $25.80 on Friday, Feb. 10, up 5 cents.

More information and details on the patent are located here under the filing with the U.S. Patent and Trademark Office.